Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
JANX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.92 - $71.71
Previous CloseN/A
Volume1.13M
Average Volume (3M)848.60K
Market Cap
$1.77B
Enterprise Value$1.85B
Total Cash (Recent Filing)$30.36M
Total Debt (Recent Filing)$25.54M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
May 13, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding59,105,150
10 Day Avg. Volume762,238
30 Day Avg. Volume848,599
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)167.13
Price to Cash Flow (P/CF)-26.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit174.46
Enterprise Value/Ebitda-19.09
Forecast
1Y Price Target
$96.78Price Target Upside204.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has a strong cash position with approximately $1.03 billion in cash and equivalents.
Market OpportunityThe pullback in Janux shares has created an attractive opportunity for investors ahead of clinical updates in 2025.
Therapeutic PotentialJanux's masked PSMA T-cell engager, JANX007, has differentiated therapeutic potential in metastatic castration-resistant prostate cancer.
Bears Say
Clinical UncertaintyThere is real outstanding clinical uncertainty for the program and emerging competitive risks.
Competitive PressureCompelling initial set of data from Vir with their dual masked HER2xCD3 and PSMAxCD3 antibodies in a large range of solid tumors, including breast, colorectal and prostate cancer, putting competitive pressure on JANX.
Stock PerformanceThe stock has significantly pulled back primarily due to the dissolution of M&A potential in the near-term and peer VIR putting out competitive data.
---
Ownership Overview
55.01% Insiders
16.40% Mutual Funds
<0.01% Other Institutional Investors
20.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $28.92 and its highest was $71.71 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Janux Therapeutics Inc’s market cap is $1.77B.
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is May 13, 2025 which is in 48 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Feb 27, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.461 by $0.101.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -0.37.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 59,105,150 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.461. Following the earnings report the stock price went up 2.749%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Currently, no hedge funds are holding shares in JANX
---
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.78 (204.91% Upside)
$96.78 (204.91% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.70%
12-Months-Change
Fundamentals
Return on Equity
-10.09%
Trailing 12-Months
Asset Growth
179.05%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
---
JANX Stock 12 Month Forecast
Average Price Target
$96.78
▲(204.91% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
I-MAB
―
Immatics
―
ALX Oncology Holdings
―
Best Analysts Covering JANX
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
+87.06%
reiterated a buy rating 23 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +87.06% per trade.
---